Figures computed from official regulatory filings — .
Analysttarget 306.87 USD (+31%) · consensus 4.76/5 · 21 buy · 0 hold · 0 sell
Ownershipinsiders 0.77% · institutions 103% · short 6.3% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Ascendis Pharma A/S only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Market information source · Oct 19, 2026
SEC company identity · Oct 19, 2026
Open-market timeline · full history
9 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BIENAIME JEAN JACQUEStrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| BIENAIME JEAN JACQUEStrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Bodenhoff Mads | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bodenhoff Mads | Exercise | $330K | SEC |
| Bodenhoff Mads | Sell | $810.6K | SEC |
| HOLTUG LARS | Sell | $62.3K | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $270.4K | conv 69Unusual size | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $222.2K | conv 58Unusual size | SEC |
| SMITH SCOTT THOMAS | Buy | $21.9K | conv 44 | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $44.5K | conv 33 | SEC |
| SMITH SCOTT THOMAS | Buy | $55.8K | conv 52First in 12mo | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $22.4K | conv 27 | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $44.8K | conv 37 | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $47.2K | conv 27 | SEC |
| BIENAIME JEAN JACQUEStrack record | Buy | $47.9K | conv 44 | SEC |
| JENSEN FLEMMING STEEN | Sell | $4.6M | SEC |